Menu
Search
|

Menu

Close
X

Corvus Pharmaceuticals Inc CRVS.OQ (NASDAQ Stock Exchange Global Market)

10.85 USD
-- (--)
As of Jul 19
chart
Previous Close 10.85
Open --
Volume --
3m Avg Volume 37,529
Today’s High --
Today’s Low --
52 Week High 17.54
52 Week Low 7.45
Shares Outstanding (mil) 20.93
Market Capitalization (mil) 348.98
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.633
FY17
-2.719
FY16
-6.884
FY15
-0.391
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
3.33
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-40.42
14.61
Return on Equity (TTM)
vs sector
-40.82
16.34

EXECUTIVE LEADERSHIP

Richard Miller
Chairman of the Board, President, Chief Executive Officer, Since 2015
Salary: $291,770.00
Bonus: --
Leiv Lea
Chief Financial Officer, Since 2015
Salary: $264,904.00
Bonus: --
Jason Coloma
Senior Vice President and Chief Business Officer, Since 2016
Salary: $214,031.00
Bonus: --
William Jones
Vice President of Pharmaceutical Development, Since 2015
Salary: --
Bonus: --
Erik Verner
Vice President of Chemistry Research, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

863 Mitten Rd Ste 102
BURLINGAME   CA   94010-1311

Phone: +1650.9004520

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

SPONSORED STORIES